REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended ...

As the world recognizes Rare Disease Day on Feb. 28, Rockville-based biotechnology company, REGENXBIO is working to change ...

ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

Regenxbio says it will now move ahead with recruiting another six patients into the phase 1/2 study, which involves administration of the gene therapy directly into the central nervous system ...

Fintel reports that on February 11, 2025, Goldman Sachs downgraded their outlook for REGENXBIO (NasdaqGS:RGNX) from Buy to Neutral. Analyst Price Forecast Suggests 370.10% Upside As of January 29, ...

Regenxbio Inc (RGNX)股价已触及52周新低，跌至6.54美元，目前市值为3.3047亿美元，该生物科技公司正面临严峻的市场环境。根据 InvestingPro ...